pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Sep 9·1 min read
save

Research on orexin and narcolepsy earns Lasker Award for Yanagisawa and Mignot

Sep 9, 2026·read at Endpoints ↗Positive

Masashi Yanagisawa and Emmanuel Mignot were honored with the Lasker Award for their work uncovering the role of orexin in narcolepsy. The award was announced on September 9, 2026.

Their research began with informal discussions in the lab and progressed through studies in mice and dogs, eventually involving the flu virus to deepen understanding of the disorder.

The findings have already been recognized with a Breakthrough Prize, highlighting the impact of this work on sleep‑disorder science and potential therapeutic approaches.

The Lasker Award underscores the importance of basic research in translating biological insights into future treatments for narcolepsy and related conditions.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Key research behind orexin and narcolepsy wins Lasker Award”

read at Endpoints ↗
91 words · retrieved Sep 9
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
PATH2Vyome Holdings, Inc

related stories

  • May 11CSL sinks to nine-year low on revenue warning, $5B write-downEndpoints
  • May 11Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapiesBioPharma Dive
  • May 11Opinion: AI doctors should be licensed. Here’s a framework to do thatSTAT
  • May 9Opinion: Dr. Glaucomflecken wants the corporatization of medicine to be national newsSTAT
  • May 9Biotech’s new company model; The super poop behind a startup launch; and moreEndpoints